Back to search

Peptide record

TPDB03432

Antibacterial Anticancer Toxicity standard
30 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB03432
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia
standard
No
A 30-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from AntiBP3 and Peptipedia, with an available 3D structural model.
Sequence
RPFTRAQIFAIQHISPRTIAMRAINNYRWR
Physicochemical Analysis
C166H263N55O39S1
DCEGLKV
R
3685.32
12.70
7
0
14
+6
1.62
-0.487
78.33
Mammalian: 1 hour Yeast: 2 min E.coli: 2 min
6990
189.67
8
Residue Composition
number
4
A
6
R
2
N
0
D
0
C
0
E
2
Q
0
G
1
H
5
I
0
L
0
K
1
M
2
F
2
P
1
S
2
T
1
W
1
Y
0
V
Amino Acid Distribution
A: 4 R: 6 N: 2 D: 0 C: 0 E: 0 Q: 2 G: 0 H: 1 I: 5 L: 0 K: 0 M: 1 F: 2 P: 2 S: 1 T: 2 W: 1 Y: 1 V: 0
Chemical Descriptors
30
C166H263N55O39S1
3685.32
12.70
+6
1.62
-0.487
Evidence Records 3 records
Evidence 1 Activity

Activity

IC50
Toxicity
>150 µM
Cytotoxic
IC50 | >150 | µM | target cell: Human fibroblasts MRC-5

Target

Human fibroblasts MRC-5

Source & Reference

NA
DBAASP
Positional scanning library applied to the human eosinophil cationic protein/RNase3 N-terminus reveals novel and potent anti-biofilm peptides. | Eur J Med Chem | 2018
Evidence 2 Activity

Activity

50% Hemolysis
Toxicity
>150 µM
Hemolytic Cytotoxic
50% Hemolysis | >150 | µM | target cell: Sheep erythrocytes

Target

Sheep erythrocytes

Source & Reference

NA
DBAASP
Positional scanning library applied to the human eosinophil cationic protein/RNase3 N-terminus reveals novel and potent anti-biofilm peptides. | Eur J Med Chem | 2018
Evidence 3 Activity

Activity

IC50
Toxicity
150 µM
Hemolytic Cytotoxic
Hemolytic_activity: Sheep erythrocytes: 50% Hemolysis>150 µM | Cytotoxicity: MRC-5: IC50>150 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
Eur J Med Chem. 2018 May 25 152:590-599.